scholarly journals Pharmacokinetics of human chorionic gonadotropin after i.m. administration in goats (Capra hircus)

Reproduction ◽  
2012 ◽  
Vol 144 (1) ◽  
pp. 77-81 ◽  
Author(s):  
M Saleh ◽  
M Shahin ◽  
W Wuttke ◽  
M Gauly ◽  
W Holtz

The present investigation addresses the pharmacokinetics of human chorionic gonadotropin (hCG), intramuscularly (i.m.) administered to goats. Nine pluriparous does of the Boer goat breed, 2–6 years of age and weighing 45–60 kg, were administered 500 IU hCG (2 ml Chorulon) deep into the thigh musculature 18 h after superovulatory FSH treatment. Blood samples were drawn from the jugular vein at 2 h intervals for the first 24 h, at 6 h intervals until 42 h, and at 12 h intervals until 114 h after administration. After centrifugation, plasma hCG concentrations were determined by electrochemiluminescence immunoassay. Pharmacokinetical parameters were as follows: lag time, 0.4 (s.e.m. 0.1) h; absorption rate constant, 0.34 (s.e.m. 0.002) h; absorption half-life, 2.7 (s.e.m. 0.5) h; elimination rate constant, 0.02 (s.e.m. 0.002) h; biological half-life, 39.4 (s.e.m. 5.1) h; and apparent volume of distribution, 16.9 (s.e.m. 4.3) l. The plasma hCG profile was characterized by an absorption phase of 11.6 (s.e.m. 1.8) h and an elimination phase of 70.0 (s.e.m. 9.8) h, with considerable individual variation in bioavailability and pharmacokinetical parameters. Biological half-life was negatively correlated (P<0.05) with peak concentration (r=−0.76), absorption rate constant (r=−0.78), and elimination rate constant (r=−0.87). The results indicate that after rapid absorption, hCG remains in the circulation for an extended period. This has to be taken into account when assessing the stimulatory response to hCG treatment on an ovarian level.

1981 ◽  
Vol 15 (12) ◽  
pp. 993-996 ◽  
Author(s):  
Robert L. Talbert ◽  
Yan Yan Wong ◽  
Douglas B. Duncan

Propranolol plasma concentrations were determined in a patient with hemolytic-uremic syndrome undergoing plasmapheresis before and after the procedure on three occasions. The mean half-life and elimination rate constant during plasmapheresis were estimated to be 25.6 percent of the values obtained without plasmapheresis. These changes suggest that plasmapheresis may influence propranolol disposition.


2013 ◽  
Vol 544 ◽  
pp. 426-430
Author(s):  
Dong Dong Jing ◽  
Yu Liu ◽  
Ruo Yu Liu ◽  
Hua Fan ◽  
Guo Feng Li ◽  
...  

The aim of this study was to observe the absorption enhancing effect of sodium dodecyl sulfate on metformin hydrochloride in colon of rat. Using in vivo intestinal loop model in rat while the ileum was took as blank group and colon as the experiment groups with different concentration of sodium dodecyl sulfate (1%, 2%, 4%). The colon/ileum ratio of the absorption rate constant of metformin hydrochloride was evaluated through calculating the residual dose of circulating solution in presupposition time points. Intergroup absorption rate constant and the rising percent of the absorption rate constant were different significantly (P<0.05). The absorption rate constant of colon were -0.22±0.03, -0.37±0.06, -0.89±0.09, -0.86±0.05μg•h-1•cm-1 (n=6) and the rising percent of the constant absorption value were 68.66 ± 8.28%, 304.88 ± 28.76%, 293.75 ± 33.19% (n=6), respectively. The result showed that the absorption of metformin hydrochloride was increased with the concentration of sodium dodecyl sulfate. However, the absorption rate constant reached maxium when the concentration of sodium dodecyl sulfate was 2%, this may be because the circulating metformin hydrochloride solution could be more viscous which affect the absorption of metformin hydrochloride when sodium dodecyl sulfate was raised. In conclusion, the absorption of metformin hydrochloride can be promoted by sodium dodecyl sulfate in the colon of rat and this can provide biophamaceutics data for novel pharmaceutical preparation.


1989 ◽  
Vol 256 (4) ◽  
pp. R1005-R1010
Author(s):  
D. Verotta ◽  
S. L. Beal ◽  
L. B. Sheiner

A semiparametric model for analysis of pharmacokinetic (PK) and pharmacodynamic (PD) data arising from non-steady-state experiments is presented. The model describes time lag between drug concentration in a sampling compartment, e.g., venous blood (Cv), and drug effect (E). If drug concentration at the effect site (Ce) equilibrates with arterial blood concentration (Ca) slower than with Cv, a non-steady-state experiment yields E vs. Cv data describing a counterclockwise hysteresis loop. If Ce equilibrates with Ca faster than with Cv, clockwise hysteresis is observed. To model hysteresis, a parametric model is proposed linking (unobserved) Ca to Cv with elimination rate constant kappa ov and also linking Ca to Ce with elimination rate constant kappa oe. When kappa oe is greater than (or less than) kappa ov clockwise (or counterclockwise) hysteresis occurs. Given kappa oe and kappa ov, numerical (constrained) deconvolution is used to obtain the disposition function of the arterial compartment (Ha), and convolution is used to calculate Ce given Ha. The values of kappa oe and kappa ov are chosen to collapse the hysteresis loops to single curves representing the Ce-E (steady-state) concentration-response curve. Simulations, and an application to real data, are reported.


1996 ◽  
Vol 30 (9) ◽  
pp. 935-940 ◽  
Author(s):  
Pina Morra ◽  
William R Bartle ◽  
Scott E Walker ◽  
S Nicole Lee ◽  
Susan K Bowles ◽  
...  

OBJECTIVE: To compare the rate and extent of systemic salicylate absorption following single and multiple applications of two topically applied analgesics, one containing methyl salicylate and the other containing trolamine salicylate. DESIGN: Two-period, two-treatment, randomized, crossover, multiple-dose study in healthy men and women volunteers. PARTICIPANTS: Six men and six women volunteers, 21–14 years of age. INTERVENTIONS: Subjects applied 5 g of an ointment containing 12.5% methyl salicylate twice daily for 4 days (8 doses) or a cream containing trolamine 10% twice daily for two doses, to a 10-cm2 area on the thigh. Treatment order and leg (right or left) were assigned randomly. Subjects were crossed over to the alternate treatment on the other leg after a minimum washout period of 7 days. MAIN OUTCOME MEASURES: The total amount of salicylate recovered in the urine during two dosing intervals (24 hours) on each study day, relative to the applied dose, was used to calculate the bioavailability of each product. Mean standard pharmacokinetic parameters including area under the curve, maximum concentration (Cmax), time to maximum concentration, and minimum concentrations at steady-state were determined from serum concentrations. Serum concentrations were fit to three pharmacokinetic models and the suitability of each model was evaluated. Estimates of absorption rate constant, clearance, volume, and fraction absorbed on day 1 were estimated by using the best-fitting model. RESULTS: Salicylic acid could not be detected in serum after trolamine application. However, concentrations between 0.31 and 0.91 mg/L were detected within 1 hour of the first application of methyl salicylate and Cmax, between 2 and 6 mg/L were observed following the seventh application on day 4. Both the extent and rate of absorption changed after the first 24 hours. The absorption rate constant increased significantly from the first to the seventh dose (first dose absorption rate constant: 0.16 h−1; seventh dose: 0.28 h−1; p < 0.035). Urinary recovery of total salicylate (salicylic acid and principal metabolites of salicylic acid) during the first 24 hours of the methyl salicylate phase averaged 175.2 mg, exceeding the 6.9 mg (p < 0.05) recovered during the trolamine phase. The recovery of salicylate in the urine in the first 24 hours after application of methyl salicylate was significantly greater than the 1.4% recovered after application of trolamine (p < 0.05). Furthermore, the fraction of methyl salicylate recovered in the urine increased significantly from 15.5% on day 1 to approximately 22% on the second, third, and fourth days. CONCLUSIONS: A considerable amount of salicylic acid may be absorbed through the skin after topical application of methyl salicylate products and this may increase with multiple applications. Caution is warranted in patients for whom systemic salicylate may be hazardous or problematic.


1997 ◽  
Vol 43 (11) ◽  
pp. 2155-2163 ◽  
Author(s):  
Juha Korhonen ◽  
Henrik Alfthan ◽  
Pekka Ylöstalo ◽  
Johannes Veldhuis ◽  
Ulf-Håkan Stenman

Abstract We have used high-specificity and precision immunofluorometric assays to measure the elimination half-times of human chorionic gonadotropin (hCG), hCGα, and hCGβ in serum over 21 days after delivery in six women with term pregnancies. Baseline concentrations and half-times were calculated with the use of a curve-fitting algorithm for multiexponential decay. In contrast to the two-component model, a three-component exponential function with baseline provided a fit for which predicted values could not be distinguished from the observed values by analysis of variance. Median half-times were 3.6, 18.0, and 53.0 h for hCG; 1.0, 23.4, and 194 h for hCGβ; and 0.6, 6.2, and 21.9 h for hCGα. The mean ratio of hCGα to hCG decreased rapidly from 36.9% to 3.3% on day 3; thereafter it increased to 64.3% 21 days after delivery because of a higher baseline concentration of hCGα. hCGβ had the slowest total elimination rate, and the ratio of hCGβ to hCG in serum increased from 0.8% before delivery to 26.7% after 21 days. If the metabolism of hCG and hCGβ is similar in patients with trophoblastic disease, the ratio of hCGβ to hCG must be evaluated with caution in samples taken several days after initiating therapy. We conclude that the disappearance of hCGβ from plasma is slower than previously recognized and that the ratios of hCGβ or hCGα to intact hCG vary as a function of postpartum time. Such information may be important in clinical studies of pregnancy disorders.


Sign in / Sign up

Export Citation Format

Share Document